Current perspectives in percutaneous atrial septal defect closure devices

N Bissessor1–4 1Department of Cardiology, The Epworth Hospital, Melbourne, VIC, Australia; 2Division of Interventional Cardiology, The Alfred Hospital, Melbourne, VIC, Australia; 3Department of Clinical Science, Charles Sturt University Albury Campus, NSW, Australia; 4Heart Foundation, Gri...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Bissessor N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/67d2ec5f7482448fa52da5ab83866e27
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:67d2ec5f7482448fa52da5ab83866e27
record_format	dspace
spelling	oai:doaj.org-article:67d2ec5f7482448fa52da5ab83866e272021-12-02T02:27:29ZCurrent perspectives in percutaneous atrial septal defect closure devices1179-1470https://doaj.org/article/67d2ec5f7482448fa52da5ab83866e272015-07-01T00:00:00Zhttp://www.dovepress.com/current-perspectives-in-percutaneous-atrial-septal-defect-closure-devi-peer-reviewed-article-MDERhttps://doaj.org/toc/1179-1470N Bissessor1–4 1Department of Cardiology, The Epworth Hospital, Melbourne, VIC, Australia; 2Division of Interventional Cardiology, The Alfred Hospital, Melbourne, VIC, Australia; 3Department of Clinical Science, Charles Sturt University Albury Campus, NSW, Australia; 4Heart Foundation, Griffith University, QLD, Australia Abstract: In the last decade, percutaneous atrial septal defect (ASD) closure has become the treatment of choice in most clinical presentations of ASD. Percutaneous ASD closure has established procedural safety through operator experience and improved device structure and deliverability. There have also been advances in diagnostic capabilities. Devices have evolved from large bulky meshes to repositionable, minimal residual mesh content that easily endothelializes and conforms well to surrounding structures. Biodegradable technology has been introduced and will be closely watched as a future option. The evolution of ASD closure device usage in the last four decades incorporates development that minimizes a wide range of serious side effects that have been reported over the years. Complications reported in the literature include thrombus formation, air embolization, device embolization, erosions, residual shunts, and nickel hypersensitivity. Modern devices have intermediate to long term data with outcomes that have been favorable. Devices are available in multiple sizes with improved delivery mechanisms to recapture, reposition, and safely close simple and complex ASDs amenable to percutaneous closure. In this review, commonly used devices and deployment procedures are discussed together with a look at devices that show promise for the future. Keywords: ASD, congenital, Amplatzer, Gore Helex, Biostar, FigullaBissessor NDove Medical PressarticleMedical technologyR855-855.5ENMedical Devices: Evidence and Research, Vol 2015, Iss default, Pp 297-303 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medical technology R855-855.5
spellingShingle	Medical technology R855-855.5 Bissessor N Current perspectives in percutaneous atrial septal defect closure devices
description	N Bissessor1–4 1Department of Cardiology, The Epworth Hospital, Melbourne, VIC, Australia; 2Division of Interventional Cardiology, The Alfred Hospital, Melbourne, VIC, Australia; 3Department of Clinical Science, Charles Sturt University Albury Campus, NSW, Australia; 4Heart Foundation, Griffith University, QLD, Australia Abstract: In the last decade, percutaneous atrial septal defect (ASD) closure has become the treatment of choice in most clinical presentations of ASD. Percutaneous ASD closure has established procedural safety through operator experience and improved device structure and deliverability. There have also been advances in diagnostic capabilities. Devices have evolved from large bulky meshes to repositionable, minimal residual mesh content that easily endothelializes and conforms well to surrounding structures. Biodegradable technology has been introduced and will be closely watched as a future option. The evolution of ASD closure device usage in the last four decades incorporates development that minimizes a wide range of serious side effects that have been reported over the years. Complications reported in the literature include thrombus formation, air embolization, device embolization, erosions, residual shunts, and nickel hypersensitivity. Modern devices have intermediate to long term data with outcomes that have been favorable. Devices are available in multiple sizes with improved delivery mechanisms to recapture, reposition, and safely close simple and complex ASDs amenable to percutaneous closure. In this review, commonly used devices and deployment procedures are discussed together with a look at devices that show promise for the future. Keywords: ASD, congenital, Amplatzer, Gore Helex, Biostar, Figulla
format	article
author	Bissessor N
author_facet	Bissessor N
author_sort	Bissessor N
title	Current perspectives in percutaneous atrial septal defect closure devices
title_short	Current perspectives in percutaneous atrial septal defect closure devices
title_full	Current perspectives in percutaneous atrial septal defect closure devices
title_fullStr	Current perspectives in percutaneous atrial septal defect closure devices
title_full_unstemmed	Current perspectives in percutaneous atrial septal defect closure devices
title_sort	current perspectives in percutaneous atrial septal defect closure devices
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/67d2ec5f7482448fa52da5ab83866e27
work_keys_str_mv	AT bissessorn currentperspectivesinpercutaneousatrialseptaldefectclosuredevices
_version_	1718402473583968256

Current perspectives in percutaneous atrial septal defect closure devices

Ejemplares similares